Elevation Oncology (NASDAQ:ELEV – Get Rating) and Cortexyme (NASDAQ:CRTX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Insider & Institutional Ownership
95.8% of Elevation Oncology shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Elevation Oncology and Cortexyme’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Elevation Oncology and Cortexyme, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Elevation Oncology currently has a consensus target price of $16.62, indicating a potential upside of 365.55%. Cortexyme has a consensus target price of $13.50, indicating a potential upside of 299.41%. Given Elevation Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe Elevation Oncology is more favorable than Cortexyme.
Valuation and Earnings
This table compares Elevation Oncology and Cortexyme’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Elevation Oncology||N/A||N/A||-$32.04 million||($6.52)||-0.55|
Elevation Oncology beats Cortexyme on 7 of the 8 factors compared between the two stocks.
Elevation Oncology Company Profile (Get Rating)
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Cortexyme Company Profile (Get Rating)
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.